B03: Multi-modal proteomics to understand and overcome nicherelatedadaptive drug-resistance mechanisms in FLT3-mutated AML

Project B03 will apply multi-modal proteomics to understand and overcome adaptive drug-resistance mechanisms in FLT3-mutated AML. Using primary AML cells, PDX and cell line models, and CRISPR-based screens, drug screens, RNAseq and proteomic approaches B03 will decipher how plasticity of FLT3-mutated AML cells leads to TKI-resistance, and will identify novel vulnerabilities in TKI-resistant cells.